In patients with T-cell ALL (T-ALL), JDP2 promoted cell survival by upregulating anti-apoptotic myeloid cell leukemia-1 (MCL1) protein. This evidence concerns the gene MCL1 and T-cell acute lymphoblastic leukemia.